DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Raised to $21.00

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) had its price target boosted by research analysts at Barrington Research from $20.00 to $21.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an "outperform" rating on the medical instruments supplier's stock. Barrington Research's price target would indicate a potential upside of 32.83% from the company's previous close.

A number of other analysts have also recently commented on the stock. Wells Fargo & Company cut their price target on shares of DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Morgan Stanley lowered shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price objective for the company. in a research note on Tuesday, April 15th. Mizuho reduced their target price on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a "neutral" rating for the company in a research report on Thursday, March 13th. Jefferies Financial Group downgraded shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $30.00 to $20.00 in a report on Thursday, January 23rd. Finally, Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a research note on Thursday, March 13th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $20.36.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $15.81 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.84 and a current ratio of 1.25. DENTSPLY SIRONA has a 52 week low of $12.16 and a 52 week high of $28.69. The firm has a fifty day moving average of $14.36 and a two-hundred day moving average of $17.54. The stock has a market capitalization of $3.15 billion, a price-to-earnings ratio of -7.64, a PEG ratio of 1.80 and a beta of 0.92.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The business had revenue of $879.00 million during the quarter, compared to analysts' expectations of $854.75 million. During the same quarter last year, the company posted $0.42 earnings per share. DENTSPLY SIRONA's quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts predict that DENTSPLY SIRONA will post 1.84 EPS for the current year.

Insider Activity at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier purchased 15,142 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 3rd. The shares were purchased at an average cost of $16.51 per share, with a total value of $249,994.42. Following the transaction, the director now owns 81,971 shares of the company's stock, valued at approximately $1,353,341.21. The trade was a 22.66% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several institutional investors and hedge funds have recently made changes to their positions in XRAY. Vanguard Group Inc. boosted its stake in DENTSPLY SIRONA by 2.8% during the first quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock valued at $309,864,000 after buying an additional 557,329 shares in the last quarter. First Eagle Investment Management LLC lifted its holdings in DENTSPLY SIRONA by 2.5% in the 4th quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier's stock worth $275,218,000 after purchasing an additional 348,532 shares during the last quarter. Nuance Investments LLC increased its position in DENTSPLY SIRONA by 25.0% in the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock worth $257,103,000 after buying an additional 2,708,097 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of DENTSPLY SIRONA by 18.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier's stock valued at $238,186,000 after purchasing an additional 1,975,404 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in DENTSPLY SIRONA by 2.8% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 11,539,418 shares of the medical instruments supplier's stock valued at $219,018,000 after buying an additional 314,343 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.